Michael A. Carson has recently been appointed as president and CEO of Centene Corporation’s Medicare business, Wellcare.
Carson, who succeeds Richard Fisher, will now be responsible for Medicare business performance, strategy and the growth of Wellcare.
Before serving nearly three decades in the healthcare industry, Carson began his career in the United States Air Force, where he served for almost a decade.
He has since developed an array of leadership, operational and industry skills in both the payer and provider space with a focus on serving Medicare and dual-eligible populations.
Carson previously held the positions of CEO at CareAbout, a value-based primary and multi-specialty care startup, as well as at Bright Health Plan and Harvard Pilgrim Health Care.
Additionally, he led the rebuilding of Medicare ventures at Amerigroup and Anthem, while also serving leadership positions at ConcertoHealth and various Blue Cross Blue Shield plans.
In a press release, Carson shared his excitement to support Wellcare’s mission to transform the health of the communities it serves.
"I look forward to helping guide the Medicare business to realize its full potential, driving further innovation and growth as we collaborate with our Medicaid and Marketplace businesses and key provider and member services partners," Carson said.
Wellcare health plans provide government-sponsored healthcare programs nationwide, with some states exclusively offering Prescription Drug Plans (PDP), while the majority offer both PDP and Medicare Advantage (MA) Plans.
Centene has expanded its Medicare presence in recent years, offering various MA products across 37 states. To enhance consumer’s healthcare experience, Centene invests in service initiatives for both members and brokers, providing affordable options for its Medicare beneficiaries.
2023 Drug Trend Report - Xevant
May 16th 2024To effectively navigate the changing pharmacy landscape and maintain a robust, cost-effective pharmacy benefit, you must understand the forces behind rising drug trend. What’s driving your costs and what can you do about it? As a leader in the PBM analytics space, we offer a unique perspective on pivotal trend drivers. Here’s what our comprehensive analysis revealed: -A surge in utilization rates across specialty and non-specialty drugs, magnified by anti-obesity therapies -Financial strain imposed by anti-inflammatory biologics and the yet-to-be-fulfilled -promise of biosimilar savings -Persistent price inflation driving higher costs year over year
Read More